/ Print /

Erin Bastick, PharmD, RPh
Autoimmune drug pipeline highlights
More targeted therapies for autoimmune diseases are on the horizon. Here’s what to anticipate in 2018.
Oncology treatments: Three areas to watch
While targeted cancer therapies make up a big part of the pipeline, there are three areas that oncology experts want you to keep on your radar.
Pediatric drug market poised for growth
More support for clinical trials and a wider lens for rare diseases in children sets the category on fire.
Oral specialty drug options on the horizon
Oral specialty drug options on the horizon
As more specialty drugs are approved, cost control strategies are key.
Brace for a barrage of biosimilars
The next few years will see the healthcare industry bracing itself for new biosimilar products for a range of illnesses from oncology to rheumatoid arthritis.
Popular insulin meets target in real-world study
Novo Nordisk’s DEVOTE study reveals interesting findings.
New universal companion diagnostic paves the way for precision oncology
FDA approves new diagnostic test for non-small cell lung cancer.
New antibiotic approved for acute bacterial skin infections
FDA approved the use of a new fluoroquinolone antibiotic to treat ABSSSI.
FDA approves Bayer’s Bluetooth-enabled auto-injector for multiple sclerosis
FDA has approved a supplemental Biologics License Application (sBLA) for Bayer’s myBETAapp and BETACONNECT Navigator for multiple sclerosis (MS) patients
Evolving hepatitis C pipeline offers hope to patients
Evolving hepatitis C pipeline offers hope to patients
Cost burden prompts payers to consider appropriate utilization